Navigation Links
Myriad Genetics Presents Mathematical Comparison of Disease,Modification Trial Designs at Alzheimer's ConferenceCurrent,Flurizan Phase 3 Study Design May Demonstrate Disease Modification

r the long-lasting benefit to the patient is maintained, demonstrating disease modification, or if the patient drops back to the level of patients on placebo for the duration of the study. In a staggered start design, one group of patients receives the active study drug for the entire study period, while a second group initially receives placebo and then later is given the active drug. If the second group fails to "catch up" in the level of performance of the first group, this is taken to be evidence for a disease modifying effect of the drug. Unfortunately, these designs are difficult to implement and have rarely been used in clinical trials as they are complicated by very long study durations, leading to high dropout rates that introduce biased results, as well as presenting ethical concerns unacceptable to patients and their families.

A team of biostatisticians and mathematicians at Myriad, led by Suzanne Hendrix, Ph.D., Sasha Gutin, Ph.D., and Scott Horton, has proposed an alternative strategy designated the "Natural History Staggered Start" analysis, that compares the slopes of decline of drug treated patients with those of patients receiving placebo and corrects for the severity of disease at baseline. The mathematical analysis presented at the Alzheimer's Association AD Prevention Conference demonstrates that this trial analysis methodology is mathematically equivalent to the "Staggered Start" and "Randomized Withdrawal" designs and provides the same level of evidence of a disease-modifying drug effect in a clinical trial that is not subject to the above-mentioned complications, bias and ethical challenges of the previous designs.

"We are excited about this persuasive mathematical comparison of clinical trial designs," said Adrian Hobden, PhD, President of Myriad Pharmaceuticals, Inc. "We believe that this mathematical proof, coupled with the Flurizan trial design may strengthen the Company's position with the FDA in favor of a disease modificat
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Myriad Genetics Presents Tumor Origin Technology at AACR
2. Myriad Genetics Presents Azixas Mode of Action at AACR
3. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
4. Genetics Journal Thimerosal/Autism Study the Best Science Drug Company Money Can Buy
5. Targeted Genetics Reports Inflammatory Arthritis Clinical Data at European Rheumatology Conference
6. ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial in B-Cell Chronic Lymphocytic Leukemia
7. Seattle Genetics Highlights Data on its Proprietary Antibody-Drug Conjugate Technology at AACR
8. Aeolus Pharmaceuticals AEOL 10150 Highlighted in Nature Genetics Publication
9. Expression Genetics, Inc. Announces Successful Completion of Phase I Trial of Gene-Based IL-12 for Treatment of Ovarian Cancer
10. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
11. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
Post Your Comments:
(Date:9/18/2014)...  Halozyme Therapeutics, Inc. (NASDAQ: HALO ... Drug Administration (FDA) has removed the clinical hold ... SWOG,s ongoing Phase 1b/2 clinical trial (S1313). The ... PEGPH20 (PEGylated Recombinant Human Hyaluronidase) in combination with ... pancreatic adenocarcinoma.  The study will resume under a ...
(Date:9/18/2014)... , September 18, 2014 After 6 ... community, we,re finally here - the new programme for the ... 2015, part of our global Cool Chain series, has just ... here ! As the lines between supply chain, ... together a programme that is broad and yet specific, focused ...
(Date:9/18/2014)... Mass. , Sept. 18, 2014  Spring ... novel therapeutics for the treatment of RNA viruses, ... Institutes of Health (NIH) for animal testing of ... viral pathogens, classified as "Special Pathogens," against which ... 9200, derived from Spring Bank,s proprietary ...
Breaking Medicine Technology:SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 2SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 3SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 4Europe's Biggest and Longest-Running Gathering of Life Sciences Logistics, Supply Chain & QA Professionals 2Spring Bank Pharmaceuticals Announces NIH Collaboration for Testing of SB 9200 Against Multiple Viral Pathogens 2
... Becomes Squarer, Makes You Look Older, ASPS,Study Reveals, ... giving away your age, and it has nothing to ... in January,s Plastic and,Reconstructive Surgery(R) (PRS), the official medical ... that as we age, the,lower jaw continues to grow, ...
... Inc.,today announced that a paper published in ... reports that SF1126, the company,s lead product,candidate, ... paper, entitled "A Vascular Targeted Pan Phosphoinositide ... Activity," is,based on preclinical studies conducted by ...
Cached Medicine Technology:Looking Older? How Square is Your Jaw Line? 2Semafore's SF1126 Exhibits Antitumor and Antiangiogenic Activity 2
(Date:9/18/2014)... HealthDay Reporter , THURSDAY, Sept. 18, 2014 ... antidepressant can quickly alter the way brain cells communicate with ... Sept. 18 in Current Biology , are a ... antidepressants. Experts said the hope is to eventually be able ... from a drug -- and which people would fare better ...
(Date:9/18/2014)... 19, 2014 In 2003, ... Mission (Misión Barrio Adentro), which it hoped ... system (see Section 6.1.3.). In 2009, it ... Autonomous Service of Pharmaceutical Elaborations (Servicio Autónomo ... provides medicines at a cheaper rate than ...
(Date:9/18/2014)... 18, 2014 Ben Quirk, CEO of ... Jr. Leadership Award by the Savannah Science Seminar in ... wellness throughout the nation and especially in Savannah. , ... said Ben. “The Savannah Science Seminar is an amazing ... multiple generations have gone through the program,” he added. ...
(Date:9/18/2014)... convene a one-day conference at the Milken Institute School ... September 25, 2014 to discuss the Global Health Security ... purpose of this event is to invite discussion of ... years, including action plans to curtail the current deadly ... GHSA, international organizations and more than 50 countries have ...
(Date:9/18/2014)... N.C. Dangerous new pathogens such as the Ebola ... ancient scourges such as the bubonic plague are still ... responds to infections. , In a study published online ... researchers at Duke Medicine and Duke-NUS Graduate Medical School ... bubonic plague hitchhike on immune cells in the lymph ...
Breaking Medicine News(10 mins):Health News:One Dose of Antidepressant Changes Brain Connections, Study Says 2Health News:One Dose of Antidepressant Changes Brain Connections, Study Says 3Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 2Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 3Health News:Venezuela Pharmaceutical Market worth $22.2 billion with 12% CAGR by 2020 Says a New Report Available at MarketOptimizer.org 4Health News:Quirk Awarded the Alex Ormond, Jr. Leadership Award by the Savannah Science Seminar 2Health News:Non-governmental stakeholders to discuss the Global Health Security Agenda 2Health News:New insights on an ancient plague could improve treatments for infections 2
... Orissa government has ordered administrations of all 30 districts to ... three days.// ,The officials were Thursday asked to ... senior health department official. ,These would then be ... government does not have testing facilities to confirm the presence ...
... safety lawyer, writes about why it is essential for us ... that there is a major defect in the food safety ... people affected or even killed by contaminated food products from ... it prevents our society from knowing the source of our ...
... of NSAID by women in their first trimester could ... ,Non-steroidal anti-inflammatory drugs, NSAIDs, Cardiac septal defects, Journal ... Congenital abnormality, Diabetes ,Women who take non-steroidal ... more likely to give birth to babies with congenital ...
... say that a commonly used HIV drug may be useful ... be used in prevention of the cancer and could be ... and his colleagues said that such a cream could prove ... lesions. However no clinical trials have begun as yet. ...
... hundreds of resident doctors in Delhi who had gone on ... agitation //for the next three months with the reservation bill ... the parliament has referred the reservation bill to the standing ... being. The bill will be placed in the floor of ...
... the University of Pennsylvania have disclosed that a specific ... of changing into bone, muscle, neurons or other// types ... environment. , ,The researchers found that ... bone marrow, are soliciting tangible clues from their local ...
Cached Medicine News:Health News:Importance of knowing the source of our food 2Health News:NSAIDs In First trimester Linked To Congenital Anomalies In Babies 2Health News:Medicos Suspends Anti-quota Stir 2Health News:Adult stem cells are sensitive to responses from the environment 2
Curved shafts with 4 mm tying platform. Serrated handle with dull finish. Manufactured in titanium. Overall length 3.3 inches....
Straight, 7 mm tying platform. Castroviejo handle. Manufactured in titanium. Overall length 4.2 inches....
Angled Castroviejo handle. Manufactured in titanium. Overall length 4.2 inches....
Straight shafts with 6 mm tying platform. Wide serrated handle with polished finish. Overall length 4.3 inches. Overall length 4.3 inches....
Medicine Products: